Oh, joy! Another riveting installment in the saga of “Can We Zap Our Way to Health?” This time, our intrepid researchers have been scouring the depths of PubMed, Scopus, and Cochrane like academic Indiana Joneses, from the ancient era of 2015 all the way to the futuristic January 2022. Their quest? To determine if transcranial direct current stimulation (tDCS) is the magic wand for fixing wonky gaits in stroke survivors.

Armed with the PRISMA statement like a treasure map, they’ve dug up 13 whole studies, with a whopping 195 RCTs. They’ve meticulously extracted data like it’s the elixir of life, using the Amstar-2 scale and the GRADE system to rate their certainty in the evidence. Spoiler alert: the certainty is about as robust as a chocolate teapot. One study reached the dizzying heights of high certainty, while five were low, and seven were critically low. It’s like a certainty limbo contest—how low can you go?

But wait, there’s a glimmer of hope! Moderate to low-quality evidence suggests tDCS might just be doing something for gait parameters. However, don’t pop the champagne just yet, because the effects are not exactly what you’d call “significant.” So, while tDCS might be making some positive changes in mobility, endurance, strength, and motor function, the researchers are basically saying, “Don’t bet your house on it.”

In conclusion, if you were hoping for a clear-cut endorsement of brain-zapping your way to better walking post-stroke, you’ll be as disappointed as a kid who got socks for Christmas. The researchers recommend that we hold our horses and wait for higher-quality studies with larger sample sizes before we start wiring everyone up. Because, as we all know, in the world of science, “more research is needed” is the catchphrase that never goes out of style.